Neoadjuvant docetaxel, oxaliplatin, and s-1 plus surgery and adjuvant s-1 for resectable advanced gastric cancer: Final survival outcomes of the randomized phase 3 PRODIGY trial.

Kang, Yoon‐Koo; Kim, Hyung‐Don; Hwan Yook, Jeong; Park, Youngkyu; Kim, Young‐Woo; Young Kim, Jin; Ryu, Min‐Hee; Young Rha, Sun; Chung, Ik‐Joo; Kim, In-Ho; Cheul Oh, Sang; Hak Yoo, Chang; Yun Kang, Seok; Young Zang, Dae; Kim, Sunju; Hoon Noh, Sung

doi:10.1200/jco.2023.41.16_suppl.4067

Public

Neoadjuvant docetaxel, oxaliplatin, and s-1 plus surgery and adjuvant s-1 for resectable advanced gastric cancer: Final survival outcomes of the randomized phase 3 PRODIGY trial.

Shared by NobleBlocks on Jun 1, 2023 • 12:00 AM UTC

Authors:

Yoon‐Koo Kang

Hyung‐Don Kim

Jeong Hwan Yook

Abstract

4067 Background: The phase 3 PRODIGY study compared neoadjuvant docetaxel, oxaliplatin and S-1 (DOS) chemotherapy followed by surgery followed by adjuvant S-1 with surgery followed by adjuvant S-1 for Korean patients with resectable locally advanced gastric cancer (LAGC) (Kang et al. J Clin Oncol. 2...

Subject

Medicine

Docetaxel

Oxaliplatin

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!